Singapore Immunology Network, Agency for Science, Technology and Research, Republic of Singapore.
Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Republic of Singapore.
Cytotherapy. 2022 Jul;24(7):711-719. doi: 10.1016/j.jcyt.2021.12.003. Epub 2022 Feb 15.
Complements and neutrophils are two key players of the innate immune system that are widely implicated as drivers of severe COVID-19 pathogenesis, as evident by the direct correlation of respiratory failure and mortality with elevated levels of terminal complement complex C5b-9 and neutrophils. In this study, we identified a feed-forward loop between complements and neutrophils that could amplify and perpetuate the cytokine storm seen in severe SARS-CoV-2-infected patients. We observed for the first time that the terminal complement activation complex C5b-9 directly triggered neutrophil extracellular trap (NET) release and interleukin (IL)-17 production by neutrophils. This is also the first report that the production of NETs and IL-17 induced by C5b-9 assembly on neutrophils could be abrogated by mesenchymal stem cell (MSC) exosomes. Neutralizing anti-CD59 antibodies abolished this abrogation. Based on our findings, we hypothesize that MSC exosomes could alleviate the immune dysregulation in acute respiratory failure, such as that observed in severe COVID-19 patients, by inhibiting complement activation through exosomal CD59, thereby disrupting the feed-forward loop between complements and neutrophils to inhibit the amplification and perpetuation of inflammation during SARS-CoV-2 infection.
补体和中性粒细胞是先天免疫系统的两个关键因素,广泛参与严重 COVID-19 发病机制的驱动,这一点可通过呼吸衰竭和死亡率与末端补体复合物 C5b-9 和中性粒细胞水平升高的直接相关性来证明。在这项研究中,我们发现了补体和中性粒细胞之间的正反馈回路,该回路可放大和持续严重 SARS-CoV-2 感染患者中出现的细胞因子风暴。我们首次观察到末端补体激活复合物 C5b-9 可直接触发中性粒细胞释放中性粒细胞胞外诱捕网(NET)并产生白细胞介素(IL)-17。这也是首次报道 C5b-9 在中性粒细胞上组装可诱导 NET 和 IL-17 的产生,而间充质干细胞(MSC)外泌体可阻断这种诱导。中和抗 CD59 抗体可消除这种阻断作用。基于我们的研究结果,我们假设 MSC 外泌体可通过外泌体 CD59 抑制补体激活来缓解急性呼吸衰竭中的免疫失调,如严重 COVID-19 患者中观察到的那样,从而破坏补体和中性粒细胞之间的正反馈回路,抑制 SARS-CoV-2 感染期间炎症的放大和持续。